![]() |
The Use of Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy for Children with a High Risk of Bleeding
Sang Taek Lee, Heeyeon Cho
Child Kidney Dis. 2014;18(2):98-105. Published online 2014 Oct 30 DOI: https://doi.org/10.3339/jkspn.2014.18.2.98
|
Citations to this article as recorded by
Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy
Mai J. Miyaji, Kentaro Ide, Kohei Takashima, Mikiko Maeno, Kelli A. Krallman, Danielle Lazear, Stuart L. Goldstein
Pediatric Nephrology.2022; 37(11): 2733. CrossRef Risk assessment of therapeutic agents under consideration to treat COVID‐19 in paediatric patients and pregnant women
Jeffrey S. Barrett
British Journal of Clinical Pharmacology.2021; 87(9): 3462. CrossRef COVID-19 Antiviral and Treatment Candidates: Current Status
Erica Españo, Dajung Kim, Jiyeon Kim, Song-Kyu Park, Jeong-Ki Kim
Immune Network.2021;[Epub] CrossRef
|